Pan Pacific Lymphoma Conference

Addition of Polatuzumab Vedotin to R-CHP Reduces Risk of Disease Progression, Death in DLBCL

July 23, 2022

Phase 3 findings from the POLARIX trial showed that the addition of platuzumab vedotin to rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a 27% reduction in risk of disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.